Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Next Previous
Trial Profile

A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 04 Jun 2024 Results of biomarker analysis for pCR in the single arm, in HER2-E eBC treated with pembrolizumab and dual HER2 blockade, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 10 Dec 2022 Results of translational subproject (n=42) assessing the gene signatures together with tumor cell proliferation and spatiotemporal immune cell profiling to identify predictive factors for pCR of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer, presented at the 45th Annual San Antonio Breast Cancer Symposium.
  • 29 Jun 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top